Lung Cancer News from Oral Sessions

Abstract LBA4 Plenary Session, Sun, 1:00 PM-4:00 PM

Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) \$ 1%: Open-label, phase 3 KEYNOTE-042 study. First Author: Gilberto Lopes, Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL


Conclusion: KEYNOTE-042 is the first study with a primary end-point of OS to demonstrate superiority of pembro over platinum-based chemo in pts with previously untreated advanced/metastatic NSCLC without sensitizing EGFR or ALK alterations and a PD-L1 TPS \geq 1%. These data confirm and potentially extend the role of pembro monotherapy as a standard first-line treatment for PD-L1-expressing advanced/metastatic NSCLC. Clinical trial information: NCT02220894

J Clin Oncol 36, 2018 (suppl; abstr LBA4)

Abstract LBA9000 Oral Abstract Session, Mon, 3:00 PM-6:00 PM

IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC. First Author: Robert M. Jotte, Rocky Mountain Cancer Centers, Denver, CO

Conclusions: IMpower131 met its co-primary endpoint of INV-assessed PFS in the ITT population in Arm B vs Arm C. The safety profile of atezo + carbo + nab-pac or pac was consistent with the known risks of the individual treatment components; no new safety signals were identified. Clinical trial information: NCT02367794



Conclusions: 1L nivo + chemo improved PFS vs chemo in pts with advanced NSCLC and NCT02477826

<u>J Clin Oncol 36, 2018 (suppl; abstr 9001)</u>